Intellia Therapeutics Inc (NASDAQ:NTLA) Director Jean Francois Formela sold 6,686 shares of the firm’s stock in a transaction on Tuesday, June 19th. The stock was sold at an average price of $27.96, for a total value of $186,940.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Jean Francois Formela also recently made the following trade(s):
- On Wednesday, May 16th, Jean Francois Formela sold 6,686 shares of Intellia Therapeutics stock. The stock was sold at an average price of $25.04, for a total value of $167,417.44.
Shares of Intellia Therapeutics opened at $27.02 on Friday, according to MarketBeat. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -14.37 and a beta of 3.21. Intellia Therapeutics Inc has a 12-month low of $14.45 and a 12-month high of $35.99.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Tuesday, May 1st. The company reported ($0.51) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.07. Intellia Therapeutics had a negative return on equity of 31.80% and a negative net margin of 278.64%. The firm had revenue of $7.47 million during the quarter, compared to analysts’ expectations of $6.14 million. equities research analysts forecast that Intellia Therapeutics Inc will post -2 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of NTLA. Farallon Capital Management LLC acquired a new stake in Intellia Therapeutics during the 4th quarter worth about $21,911,000. ARK Investment Management LLC lifted its position in Intellia Therapeutics by 269.2% during the 4th quarter. ARK Investment Management LLC now owns 1,375,149 shares of the company’s stock worth $26,430,000 after acquiring an additional 1,002,671 shares during the period. Federated Investors Inc. PA lifted its position in Intellia Therapeutics by 49.5% during the 1st quarter. Federated Investors Inc. PA now owns 598,100 shares of the company’s stock worth $12,614,000 after acquiring an additional 198,100 shares during the period. Sphera Funds Management LTD. acquired a new stake in Intellia Therapeutics during the 1st quarter worth about $3,374,000. Finally, Shellback Capital LP acquired a new stake in Intellia Therapeutics during the 4th quarter worth about $2,343,000. 60.74% of the stock is owned by institutional investors.
Several research analysts have commented on the company. BidaskClub upgraded Intellia Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 16th. ValuEngine upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Intellia Therapeutics in a report on Friday, May 18th. Chardan Capital raised Intellia Therapeutics from a “neutral” rating to a “buy” rating in a research report on Tuesday, May 15th. Finally, TheStreet cut Intellia Therapeutics from a “c-” rating to a “d” rating in a research report on Monday, May 7th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Intellia Therapeutics currently has an average rating of “Buy” and an average price target of $34.83.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.